The Spanish Sincrolab, a company that develops advanced digital solutions for mental health disorders, has received CE marking for its therapy digital versus Attention Deficit Hyperactivity Disorder (ADHD), ‘Sea of Heroes: new world’. It is the first national company to receive this certification for a mental health treatment based on artificial intelligence and video games.
The Spanish Federation of ADHD Associations points out that 5.9% of minors and adolescents and 2.8% of adults suffer from this mental disorder. Today, to treat this pathology there are two types of medications: psychostimulants (methylphenidate and lisdexamfetamine) and non-stimulants (atomoxetine and guanfacine, among others).
Sincrolab has invested more than one million euros in the creation of this therapy, As explained by the company to elEconomista.es. It is designed to improve the cognitive and behavioral functions of children, adolescents and adults with ADHD. Combines artificial intelligence with a video game experience. Furthermore, this device aims to offer a non-pharmacological, effective and evidence-based solution for people who need to improve impulsivity control and the ability to concentrate.
It is worth mentioning that this device will require a medical prescription and will be available starting December 1 of this year.
Research and development
Syncrolab conducted several clinical trials to obtain authorization for this therapy. In fact, the UPM Biomedical Technology Center and the Cognitive and Computational Neuroscience Laboratory of the Complutense University of Madrid (UCM) participated.
Studies demonstrated the effectiveness of this therapy in improving cognitive functions in patients with ADHD. He showed a significant reduction of impulsivity and a strengthening of inhibitory control. What’s more, seven out of ten patients reduced their impulsivity and 28% reached levels considered neurotypical. Also 60% demonstrated clinical improvements in symptom reduction.
The neuroscientist and researcher at the Cognitive and Computational Neuroscience Laboratory and main author of the latest study says that “we observed that, in patients assigned to Sincrolab therapy, improvements in impulsivity and inhibitory control were associated with a greater reduction in electrophysiological activity. in the alpha and beta frequencies, which suggests a functional reorganization of the neural networks.”
On the other hand, andThis is not the only treatment being investigated Synchrolab. In addition, they are developing products for mild cognitive impairment, stroke and other neurological pathologies. “Without a doubt, this is just the beginning within the framework of our firm commitment to contributing to the mental well-being of all people who need it through effective and accessible digital tools. We continue to advance in the accessibility of increasingly better treatments to all patients who need it, wherever they are,” says Sincrolab CEO, Ignacio de Ramón.
#Spanish #company #Sincrolab #receives #European #approval #digital #treatment #ADHD
